Ambys Medicines
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Research and development of regenerative and restorative therapies.
02 / Ambys Medicines FAILURE REASONS
Failure reasons
Ambys was a high-risk, capital-intensive 'moonshot' pursuing three unproven approaches to liver regeneration at once: cell therapy, gene therapy, and small molecules. Its lead hepatocyte-replacement cell therapy, expected to reach the clinic in the second quarter of 2022, never made it there. According to a former employee, the company 'could not convince investors to bring this transformative therapy to patients at this time,' while a former executive attributed the shutdown to 'a set of unfortunate circumstances.' The closure came during a difficult 2022-2023 biotech funding environment in which many drug developers were laying off staff or shutting down, and no successor financing materialized to carry the programs forward.
03 / EVENT HISTORY
Events in the structured record
- Operations closed
The Rochester Post Bulletin reported on 27 Feb 2023 that South San Francisco liver-cell therapy biotech Ambys Medicines, Inc. (founded 2018) quietly closed its doors at the end of 2022, describing it as a defunct company whose intellectual-property assets were then acquired by Cytotheryx.
- Asset sale
Cytotheryx announced on 23 Feb 2023 that it had acquired Ambys Medicines, Inc. intellectual-property assets after the company had already closed; this is an asset purchase of a defunct biotech, not an operating going-concern acquisition.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Ambys closed operations in February 2023, about five years after its 2018 launch, without a major public disclosure; employees signaled the closure on professional networking sites.
- 02
On February 23, 2023, Cytotheryx, Inc. of Rochester, Minnesota announced it had acquired Ambys Medicines' intellectual property assets, ending the company's independent existence.
- 03
Over its lifetime the company raised about $187 million, including the $60 million Series A and $80 million Takeda partnership commitment at launch plus a $47 million capital haul announced in December 2021.